Cellular Vaccine and Method of Inducing an Immune Response in a Subject (formerly referred to as Suicide Gene NSP4 as an Augment for DNA Vaccines)


Technology Overview
Our cytolytic DNA vaccines encode a viral immunogen and a cytolytic protein to induce necrosis in targeted cells resulting in release of a range of damage associated molecular patterns (DAMPs) and cross presentation of the immunogen.  This results in increased virus-specific immune responses.  The goal is to attract circulating dendritic cells (DC) to the site of vaccination and induce a degree of inflammation.  This mimics the effect of live attenuated viral vaccines (which are nevertheless cytolytic and result in the extracellular appearance of DAMPs-natural adjuvants) and generates high levels of cellular immunity. 


Potential Applications 

The technology is a vaccine used to generate expression of endogenous proteins. The invention is designed to increase the efficiency of DNA vaccination via the differential efficiency of two promoters, and vaccination by virus vectors for prevention of persistent viral infections such as HIV, Hepatitis C, and Influenza. 


Key Features & Benefits 
DNA vaccines show exciting translational prospects for development of effective vaccines to prevent establishment of persistent infection.  Key features and benefits include the following:

•       Generates higher levels of cell-mediated immunity (CMI)

•       Elicits greater protection against challenge

•       Encodes multiple immunogenic proteins and elicits CMI against each of the encoded proteins

•       More reproducible, long-term immunity

•       Elicits multigenotypic responses more effectively

•       Stable, simple and inexpensive.

•       Can be deployed rapidly

•       Excellent safety profile



View Briefing document here.

Patent Information:
Drug Discovery
For Information, Contact:
Michael Muthig
Commercial Manager
The University of Adelaide
Eric Gowans